Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD

NCT03051256 is registered in ClinicalTrials.gov with Relmada Therapeutics, Inc. as lead sponsor.

NCT NCT03051256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03051256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Lead sponsor
Relmada Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 11, 2018
Completion date
September 30, 2019
Enrollment
62 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major, depressive disorder, treatment-resistant